Amgen To Participate In Citi Biotech R&D Conference Call
Get Alerts AMGN Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 3%
Revenue Growth %: +2.7%
Join SI Premium – FREE
THOUSAND OAKS, Calif., Oct. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will participate in a call hosted by Citi at 8 a.m. PT on Friday, Oct. 7, 2016. Sean E. Harper, M.D., executive vice president of Research and Development (R&D) at Amgen, will discuss recent developments within the Company's R&D. Live audio of the call can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand OaksKristen Davis, 805-447-3008 (media)Kristen Neese, 805-313-8267 (media)Arvind Sood, 805-447-1060 (investors)
Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amgen-to-participate-in-citi-biotech-rd-conference-call-300339149.html
SOURCE Amgen
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agility Robotics to go public via $2.5B SPAC merger
- Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump Ahead of Commercial Expansion
- RAEK Launches AI Agents Built on the Data Businesses Actually Own
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Citi, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share